<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997630</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC18.0159 ( TrOMaTho)</org_study_id>
    <nct_id>NCT03997630</nct_id>
  </id_info>
  <brief_title>Management of Moderately Hypoxemic Thoracic Trauma</brief_title>
  <acronym>TrOMaTho</acronym>
  <official_title>Post Traumatic Early Use of High Flow Oxygenation Versus Standard Oxygen for Management of Moderately Hypoxemic Thoracic Trauma: TrOMaTho Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, the average incidence of thoracic trauma is 10,000 to 15,000 each year. These
      patients are at risk of early and late post traumatic respiratory complications as follows:
      pneumonia, Acute Respiratory Distress Syndrome (ARDS), hypoxemia. Main issues of thoracic
      trauma management were recently published by French anesthesiologist and intensivist experts.
      Non-invasive ventilation (NIV) was recommended in case of severe hypoxemia (PaO2/FiO2 &lt; 200).
      In comparison to conventional oxygenation or mechanical ventilation, NIV reduced length of
      stay, incidence of complications and mortality in case of severe hypoxemia. For mild or
      moderate hypoxemic patients, no devices were tested to prevent respiratory complications. At
      the moment, low-flow oxygenation is administered to these patients in the absence of severe
      hypoxemia. Recently, many studies have found promising results with high-flow oxygenation
      delivered by nasal cannula. This device has many physiological advantages: wash out the
      naso-pharyngeal dead space, increase end expiratory lung volume, deliver a moderate or low
      level of Positive end-expiratory pressure (PEEP), improve work of breathing and confort.
      Several randomized controlled trials tested this device in many clinical settings, but there
      are no studies on its use after thoracic trauma. A comparative trial is needed to evaluate
      early prophylactic administration of high-flow oxygenation after thoracic trauma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TrOMaTho study is an investigator-initiated, randomized, unblinded, controlled trial. The aim
      of this study is to compare a prophylactic use of high-flow nasal cannula oxygenation
      (experimental group) to low-flow oxygenation (control group) after thoracic trauma. 770
      patients will be included. Randomization will be conducted with random block and patients
      will be randomized in 1:1 ratio in one of the two groups. Randomization process will be
      stratified on: age (more or less 65 years old), use of peridural analgesia and existence of
      extra thoracic trauma. Only the oxygenation technique is studied, all other aspects of
      management will be handle by the attending physician.

      All patients will be followed from enrollment to hospital discharge. To ensure the same data
      collection in all centers, six visits are planned: day (D) 1 (inclusion), D7, D14, D28.

      Classical blinded methods cannot be used for the evaluation of these kinds of devices. To
      ensure the same evaluation for all patients and in all centers, all relevant outcomes will be
      evaluated by an independent clinical event committee. Statistical analysis will be performed
      by an independent statistician.

      Primary endpoint will be analyzed according to intention to treat. Secondary outcomes will be
      analyzed as exploratory analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety event</measure>
    <time_frame>Day 28</time_frame>
    <description>The primary endpoint is a composite endpoint defined by:
The use of non-invasive ventilation whatever the cause before the 14th day following the trauma (yes/no) OR
The use of orotracheal intubation whatever the cause before the 14th day following on the thoracic traumatism.(yes/no) OR
The death any cause confused with D28. (yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe hypoxemia</measure>
    <time_frame>day 7</time_frame>
    <description>Severe hypoxemia before day 7: SpO2 &lt; 92% or PaO2/FiO2 &lt; 200 without oxygenation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypoxemia</measure>
    <time_frame>day 14</time_frame>
    <description>Severe hypoxemia before day 14: SpO2 &lt; 92% or PaO2/FiO2 &lt; 200 without oxygenation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory tract infection</measure>
    <time_frame>day 7</time_frame>
    <description>Respiratory tract infection before day 7 defined according to international recommendations on health-associated pneumonia or trachea-bronchitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory tract infection</measure>
    <time_frame>day 14</time_frame>
    <description>Respiratory tract infection before day 14 defined according to international recommendations on health-associated pneumonia or trachea-bronchitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>day 7</time_frame>
    <description>Need for mechanical ventilation before day 7. Criteria used to define the need of mechanical ventilation is an acute respiratory distress defined as: the inability to clear tracheal secretion, a deterioration of neurological status (decrease in GCS of 2 points), a respiratory acidosis (pH &lt; 7,25 and PaCO2 &gt; 45 mmHg), signs of persisting or worsening respiratory failure (respiratory rate &gt; 35/min, high respiratory-muscle workload) with a poor response to another oxygenation device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>day 14</time_frame>
    <description>Need for mechanical ventilation before day 14. Criteria used to define the need of mechanical ventilation is an acute respiratory distress defined as: the inability to clear tracheal secretion, a deterioration of neurological status (decrease in GCS of 2 points), a respiratory acidosis (pH &lt; 7,25 and PaCO2 &gt; 45 mmHg), signs of persisting or worsening respiratory failure (respiratory rate &gt; 35/min, high respiratory-muscle workload) with a poor response to another oxygenation device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen free days</measure>
    <time_frame>day 14</time_frame>
    <description>number of day without oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilator free days</measure>
    <time_frame>day 14</time_frame>
    <description>number of day without ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>day 90</time_frame>
    <description>number of day in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>day 90</time_frame>
    <description>number of day of the total stay in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause of mortality</measure>
    <time_frame>day 28 or day 90</time_frame>
    <description>Mortality (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life 3 months after High flow oxgenation with the The Short Form (36) Health Survey score</measure>
    <time_frame>day 90</time_frame>
    <description>SF 36 questionnary total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of dyspnea using a Saint Georges respiratory questionnaire</measure>
    <time_frame>day 90</time_frame>
    <description>Saint Georges questionnary total score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">770</enrollment>
  <condition>Chest Trauma</condition>
  <condition>High Flow Oxygenation</condition>
  <arm_group>
    <arm_group_label>Interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group: All patients included in this group will receive a low flow oxygenation (flow rate &lt; 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow Oxygenation</intervention_name>
    <description>Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.</description>
    <arm_group_label>Interventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard oxygen</intervention_name>
    <description>Control group: All patients included in this group will receive a low flow oxygenation (flow rate &lt; 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patient (age ≥ 18 years),

          -  Admitted to intensive care unit for less than 48 hours for the management of chest
             trauma.

          -  Closed chest trauma, non-penetrating, with a TTSS score&gt; or equal to 4.

          -  Need for conventional oxygen therapy to maintain SpO2 greater than or equal to 95%.

          -  Patient affiliated or beneficiary of a social security scheme

          -  Patient having signed a consent

        Exclusion Criteria:

          -  Severe hypoxemia defined as a PaO2/FiO2 ratio &lt; 200.

          -  Recommended indication for NIV: cardiogenic pulmonary oedema, decompensated COPD.

          -  Indication to immediate oro-tracheal intubation. In the particular case of an IOT for
             surgery, also will be excluded patients requiring thoracic or abdominal surgery by
             laparotomy during the first 48 hours (will not be excluded patients requiring general
             anaesthesia for a surgical procedure for a peripheral surgical procedure or
             embolization)

               -  Patient with acute respiratory distress, whatever the cause.

               -  Hemodynamic instability marked by a fall of the PAS&gt; 30% or a PAS &lt;110 mmHg
                  despite the initial resuscitation measures

               -  Neurological degradation with Glasgow score less than 12

          -  Pregnant or lactating woman

          -  Patient under guardianship or curatorship

          -  Contraindication to the use of one or both devices studied (decaying facial trauma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Véronique Vermeersch, Dr</last_name>
    <phone>+33298347288</phone>
    <email>veronique.vermeersch@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier Huet, Pr</last_name>
    <phone>+33298347288</phone>
    <email>olivier.huet@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <state>Bretagne</state>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikaël Moriconi, MD</last_name>
      <phone>+33298526515</phone>
      <email>m.moriconi@chcormouaille.fr</email>
    </contact>
    <investigator>
      <last_name>Mikaël Moriconi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angers university hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brest university hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Huet, MD,PhD</last_name>
      <phone>+33298347288</phone>
      <email>olivier.huet@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Huet, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Vermeersch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chartres Hospital</name>
      <address>
        <city>Chartres</city>
        <zip>28000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Kalfon, MD</last_name>
      <phone>+33237303073</phone>
      <email>pkalfon@ch-chartres.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Kalfon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre PASQUIER, MD, PhD</last_name>
      <phone>+33 1 41466726</phone>
      <email>pasquier9606@me.com</email>
    </contact>
    <investigator>
      <last_name>Pierre PASQUIER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dreux hospital</name>
      <address>
        <city>Dreux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aude GARIN, MD, PhD</last_name>
      <phone>+33473750476</phone>
      <email>AGARIN@ch-dreux.fr</email>
    </contact>
    <investigator>
      <last_name>GARIN Aude, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Mans hospital</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlène LE MOAL, MD</last_name>
      <email>clemoal@ch-lemans.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mickael Landais, MD</last_name>
      <phone>+33243432458</phone>
      <email>mlandais@ch-lemans.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Charlène LE MOAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mickael Landais, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Bouju, MD</last_name>
      <email>p.bouju@ch-bretagne-sud.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Bouju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marseille university horpital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary DUCLOS, MD, PhD</last_name>
      <email>gary.duclos@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marc LEONE</last_name>
      <email>marc.leone@ap-hm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Gary DUCLOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc LEONE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Charbit, MD</last_name>
      <phone>+33467338256</phone>
      <email>j-charbit@chumontpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Jonathan Charbit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morlaix hospital</name>
      <address>
        <city>Morlaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Yves Egreteau, MD</last_name>
      <phone>+33298626095</phone>
      <email>PEgreteau@ch-morlaix.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Yves Egreteau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes university hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Asehnoune, MD, PhD</last_name>
      <phone>+33240083005</phone>
      <email>karim.asehnoune@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Karim Asehnoune, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de la Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kremlin Bicêtre university hospital (APHP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Duranteau, MD, PhD</last_name>
      <phone>+33145213936</phone>
      <email>jacques.duranteau@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Duranteau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes, university Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas LEBOUVIER, MD</last_name>
      <email>thomas.lebouvier@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Philippe SEGUIN, MD,PhD</last_name>
      <email>philippe.seguin@chu-rennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas LEBOUVIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe SEGUIN, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours university hospital</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine Ferrandiere, MD, PhD</last_name>
      <phone>+33247475997</phone>
      <email>m.ferrandiere@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Martine Ferrandiere, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHBA de Vannes</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angélique GOEPP, MD</last_name>
      <phone>+33297014306</phone>
      <email>angelique.goepp@ch-bretagne-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>Angélique GOEPP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning five years and ending fifteen years following the final study report completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

